Molecular Analysis of Gastric and OEsophageal Cancers STudy

Royal Marsden NHS Foundation Trust

Overview

A prospective translational tissue collection study to identify biomarkers predictive of treatment response/resistance and biomarkers of prognostic value from a series of patients who are investigated for and diagnosed with early or advanced gastric/junctional or oesophageal cancer (oesophagogastric cancer) at The Royal Marsden Hospital.

Tissue samples and biological specimens (which may include blood, stool, saliva) from patients with a suspected/confirmed oesophagogastric cancer (OGC) at The Royal Marsden NHS Foundation Trust over the study period will be collected and stored on behalf of The Royal Marsden NHS Foundation Trust. Molecular analyses including, but not limited to, miRNA analysis, DNA and RNA sequencing, nanostring, RT-PCR and immunohistochemistry will be carried out. Stool and saliva samples may be analysed to assess the microbiota present. Molecular analyses data and microbiota data will be collated in a link-anonymised manner and correlated to clinical outcome data. This prospective study is intended to set up a database of patients treated both for oesophageal cancer and gastric cancer with availability of annotated clinical data and tumour tissue plus biological specimens. This series will serve as a valuable platform to analyse the expression of several biomarkers of potential interest. There will also be the opportunity to assess the prognostic and predictive role of identified biomarkers in specific patient subgroups and in relation to specific treatments. Within this study, we may also hope to develop organoid and patient derived xenograft models to represent locally advanced and metastatic disease which will support future drug development. We aim to also investigate the microbiome of patients diagnosed with OGC. In addition, this database can serve as a validation cohort for the external validation of findings from other projects in OGC which are of clinical relevance. The molecular analysis plans for the study will develop as the study progresses and as new data emerges which will generate new hypotheses to investigate.

Study Type

OBSERVATIONAL

Conditions

Adenocarcinoma Esophagus Adenocarcinoma of the Stomach Adenocarcinoma - GEJ Squamous Cell Car. - Esophagus

Interventions

biopsyDIAGNOSTIC_TEST

Baseline biopsy and biological specimens

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patient is being investigated/treated for OGC at The Royal Marsden Hospital during the study period. 2. Patient has an oesophageal/gastric mass or metastasis amenable to core needle biopsy or surgery. 3. Patient is clinically fit enough to undergo a tumour biopsy or surgery (if not already performed) according to investigator assessment and local guidelines. 4. Patient is ≥ 18 years of age. 5. Patient is able to understand the information provided within the patient information sheet and is able to provide written informed consent. 6. Patient has sufficient tissue for analysis. Exclusion Criteria: 1. Patients who are not treated at The Royal Marsden Hospital or referring centre. 2. Patients who have a second active malignancy other than oesophageal/gastric cancer. 3. Patients who have one or more contraindications to a tumour biopsy or surgery (if not already performed) according to local guidelines. 4. Patients with an uncontrolled concomitant medical condition including, but not limited to, ongoing or active infection not amenable to standard antibiotic therapy, irreversible increased risk of bleeding which prevents biopsy as per standard procedures, or a psychiatric illness or social situation that could affect compliance with study procedures.

Locations (1)

Royal Marsden NHS Foundation Trust - London

London, United Kingdom

Outcomes

Primary Outcomes

The prevalence and distribution of biomarkers potentially prognostic or predictive of treatment response/resistance in a large series of patients with OGC

Time frame: 5 years

Secondary Outcomes

Disease control rate (CR, PR and SD) in locally advanced/metastatic disease

Time frame: 5 years

Duration of response (CR/PR) in locally advanced/metastatic disease

Time frame: 5 years

Progression free survival (PFS) in locally advanced/metastatic disease

Time frame: 5 years

Relapse free survival (RFS) in early stage curative disease

Time frame: 5 years

Overall Survival (OS) according to stage of disease

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.